Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

186.06 +5.69 (+3.15%)
Official Closing Price Updated: 7:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
78 79 Next >
Forget Nvidia, Buy This Magnificent Healthcare Stock Instead
AbbVie's returns haven't been great this year, but investors shouldn't overlook this promising growth stock. 
Via The Motley Fool
Evolus: Chiseling Away At The Aesthetic Market
Via Talk Markets
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These dividend stocks are ideal for investors seeking long-term passive income. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
Via Benzinga
Topics Data Breach
Exposures Information Security
This Is What Whales Are Betting On AbbVie
Via Benzinga
A Must-Own Stock for Any Portfolio
This company offers growth, high yield, and dividend growth. 
Via The Motley Fool
2 Billion More Reasons to Buy AbbVie Stock
This pharma giant just made a smart strategic acquisition. 
Via The Motley Fool
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
3 Biotech Stocks to Buy on the Dip: May 2024
These biotech giants offer investors the best opportunity money can buy for excellent profits and returns this year. 
Via InvestorPlace
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Analyst Verdict: AbbVie In The Eyes Of 5 Experts
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,000 Today
Via Benzinga
Unpacking the Latest Options Trading Trends in AbbVie
Via Benzinga
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
From FN Media Group LLC
Via GlobeNewswire
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them. 
Via InvestorPlace
7 Safe-Haven Stocks to Weather Any Storm
Explore top safe-haven stocks to buy now for stability and consistent growth during economic turbulence and uncertainty. 
Via InvestorPlace
3 S&P 500 Stocks That Have Proven Themselves Recession-Proof
Corrections are a part of investing and investors would be smart to have these three S&P 500 stocks to buy when the inevitable happens. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Revenue growth during what should be a disastrous patent cliff is encouraging. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). 
Via Benzinga
Topics Cannabis
Exposures Cannabis
10 Stocks to Build a Dividend Portfolio With
All 10 of these stocks pay reliable and growing dividends. 
Via The Motley Fool
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine,... 
Via Benzinga
7 Value Stocks to Buy and Hold for a Decade of Dominance
Discover the enduring value of seven key value stocks to buy and hold in diverse sectors, presenting unparalleled opportunities. 
Via InvestorPlace
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for May 2024
Amid the strong run in the market, investors thinking about long-term goals should consider these strongly endorsed retirement stocks to buy. 
Via InvestorPlace
Topics Retirement
Exposures Pension
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
3 Magnificent Stocks That Are Passive Income Machines
These three companies have track records that should please investors. 
Via The Motley Fool
What Is the Dividend Payout for AbbVie Stock?
The pharmaceutical company isn't just a quality healthcare holding. It's a compelling income investment as well. 
Via The Motley Fool
Healthcare And Biotech Investing 101: What You Need To Know.
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Earn $1000 Every Month From These 3 Stocks
All 3 companies pay growing dividends. 
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
These pharmaceutical companies are top-notch dividend growth stocks for the future. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
78 79 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.